CHK1 Inhibition Synergizes with Gemcitabine Initially by Destabilizing the DNA Replication Apparatus.

@article{Koh2015CHK1IS,
  title={CHK1 Inhibition Synergizes with Gemcitabine Initially by Destabilizing the DNA Replication Apparatus.},
  author={Siang-Boon Koh and Aur{\'e}lie Courtin and Richard J Boyce and Robert George Boyle and Frances M. Richards and Duncan I. Jodrell},
  journal={Cancer research},
  year={2015},
  volume={75 17},
  pages={3583-95}
}
Combining cell-cycle checkpoint kinase inhibitors with the DNA-damaging chemotherapeutic agent gemcitabine offers clinical appeal, with a mechanistic rationale based chiefly on abrogation of gemcitabine-induced G2-M checkpoint activation. However, evidence supporting this mechanistic rationale from chemosensitization studies has not been consistent. Here we report a systematic definition of how pancreatic cancer cells harboring mutant p53 respond to this combination therapy, by combining… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-8 of 8 extracted citations

Targeting cell cycle dependencies represent a novel therapeutic approach for selected sarcoma subgroups.

Annals of oncology : official journal of the European Society for Medical Oncology • 2018
View 2 Excerpts

References

Publications referenced by this paper.
Showing 1-10 of 36 references

Enhancement of cisplatin-induced cytotoxicity by 7-hydroxystaurosporine (UCN-01), a new G2-checkpoint inhibitor.

Clinical cancer research : an official journal of the American Association for Cancer Research • 1996
View 1 Excerpt
Highly Influenced

Metronomics: towards personalized chemotherapy?

Nature Reviews Clinical Oncology • 2014
View 1 Excerpt

Similar Papers

Loading similar papers…